Long noncoding RNA LINC01291 promotes the aggressive properties of melanoma by functioning as a competing endogenous RNA for microRNA-625-5p and subsequently increasing IGF-1R expression.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
06
10
2020
accepted:
16
02
2021
revised:
27
01
2021
pubmed:
7
3
2021
medline:
12
4
2022
entrez:
6
3
2021
Statut:
ppublish
Résumé
Studies have confirmed the relationship between dysregulated long noncoding RNAs and melanoma pathogenesis. However, the regulatory functions of long intergenic non-protein coding RNA 1291 (LINC01291) in melanoma remain unknown. Therefore, we evaluated LINC01291 expression in melanoma and explored its roles in regulating tumor behaviors. Further, the molecular events via which LINC01291 affects melanoma cells were investigated. LINC01291 expression in melanoma cells was analyzed using The Cancer Genome Atlas database and quantitative real-time polymerase chain reaction. Functional assays, including the Cell Counting Kit-8 assay, colony formation assay, flow cytometry, cell migration and invasion assays, and tumor xenograft models, were used to examine LINC01291's role in melanoma cells. Additionally, bioinformatics analysis, RNA immunoprecipitation, luciferase reporter assay, and western blotting were conducted to determine the tumor-promoting mechanism of LINC01291. LINC01291 was upregulated in melanoma tissues and cell lines. Following LINC01291 knockdown, cell proliferation, colony formation, migration, and invasion were diminished, whereas apoptosis was enhanced and the cell cycle was arrested at G0/G1. In addition, loss of LINC01291 decreased the chemoresistance of melanoma cells to cisplatin. Furthermore, LINC01291 interference inhibited melanoma tumor growth in vivo. Mechanistically, LINC01291 functions as a competing endogenous RNA by sponging microRNA-625-5p (miR-625-5p) in melanoma cells and maintaining insulin-like growth factor 1 receptor (IGF-1R) expression. Rescue experiments revealed that the roles induced by LINC01291 depletion in melanoma cells could be reversed by suppressing miR-625-5p or overexpressing IGF-1R. Our study identified the LINC01291/miR-625-5p/IGF-1R competing endogenous RNA pathway in melanoma cells, which may represent a novel diagnostic biomarker and an effective therapeutic target for melanoma.
Identifiants
pubmed: 33674778
doi: 10.1038/s41417-021-00313-9
pii: 10.1038/s41417-021-00313-9
pmc: PMC8940622
doi:
Substances chimiques
IGF1R protein, human
0
MIRN625 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
Receptor, IGF Type 1
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-357Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc. part of Springer Nature.
Références
Owens B. Melanoma. Nature. 2014;515:S109.
pubmed: 25407704
doi: 10.1038/515S109a
Mohammadpour A, Derakhshan M, Darabi H, Hedayat P, Momeni M. Melanoma: where we are and where we go. J Cell Physiol. 2019;234:3307–20.
pubmed: 30362507
doi: 10.1002/jcp.27286
Arnold J, Engelmann JC, Schneider N, Bosserhoff AK, Kuphal S. miR-488-5p and its role in melanoma. Exp Mol Pathol. 2019;112:104348.
pubmed: 31765608
doi: 10.1016/j.yexmp.2019.104348
Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, et al. Melanoma epidemiology and prevention. Cancer Treat Res. 2016;167:17–49.
pubmed: 26601858
doi: 10.1007/978-3-319-22539-5_2
Eggermont AM, Suciu S, Rutkowski P, Kruit WH, Punt CJ, Dummer R, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111–21.
pubmed: 26790144
doi: 10.1016/j.ejca.2015.11.014
Rozeman EA, Dekker TJA, Haanen J, Blank CU. Advanced melanoma: current treatment options, biomarkers, and future perspectives. Am J Clin Dermatol. 2018;19:303–17.
pubmed: 29164492
doi: 10.1007/s40257-017-0325-6
Wang Y, Liu M, Chen S, Wu Q. Plantamajoside represses the growth and metastasis of malignant melanoma. Exp Ther Med. 2020;19:2296–302.
pubmed: 32104297
pmcid: 7027332
Diederichs S. The four dimensions of noncoding RNA conservation. Trends Genet. 2014;30:121–3.
pubmed: 24613441
doi: 10.1016/j.tig.2014.01.004
Castro-Oropeza R, Melendez-Zajgla J, Maldonado V, Vazquez-Santillan K. The emerging role of lncRNAs in the regulation of cancer stem cells. Cell Oncol. 2018;41:585–603.
doi: 10.1007/s13402-018-0406-4
Jiao D, Liu Y, Tian Z. microRNA-493 inhibits tongue squamous cell carcinoma oncogenicity via directly targeting HMGA2. Onco Targets Ther. 2019;12:6947–59.
pubmed: 31695410
pmcid: 6717877
doi: 10.2147/OTT.S210567
Suarez B, Prats-Mari L, Unfried JP, Fortes P. LncRNAs in the type I interferon antiviral response. Int J Mol Sci. 2020;21:6447
pmcid: 7503479
doi: 10.3390/ijms21176447
Liu L, Zhang D, Li Y. LncRNAs in cardiac hypertrophy: from basic science to clinical application. J Cell Mol Med. 2020;24:11638–45.
pubmed: 32896990
pmcid: 7579708
doi: 10.1111/jcmm.15819
Ruhle F, Stoll M. Long non-coding RNA databases in cardiovascular research. Genomics Proteomics Bioinformatics. 2016;14:191–9.
pubmed: 27049585
pmcid: 4996844
doi: 10.1016/j.gpb.2016.03.001
Nagpal N, Agarwal S. Telomerase RNA processing: implications for human health and disease. Stem Cells. 2020;38:1532–43.
doi: 10.1002/stem.3270
Merdrignac A, Papoutsoglou P, Coulouarn C. Long non-coding RNAs in cholangiocarcinoma. Hepatology. 2020. Online ahead of print.
Yang X, Xie Z, Lei X, Gan R. Long non-coding RNA GAS5 in human cancer. Oncol Lett. 2020;20:2587–94.
pubmed: 32782576
pmcid: 7400976
doi: 10.3892/ol.2020.11809
Ma DM, Sun D, Wang J, Jin DH, Li Y, Han YE. Long non-coding RNA MIR4435-2HG recruits miR-802 from FLOT2 to promote melanoma progression. Eur Rev Med Pharm Sci. 2020;24:2616–24.
Chen XE, Chen P, Chen S, Lu J, Ma T, Shi G. et al. Long non-coding RNA FENDRR inhibits migration and invasion of cutaneous malignant melanoma cells. Biosci Rep. 2020;40:BSR20191194.
pubmed: 32134466
pmcid: 7080643
doi: 10.1042/BSR20191194
Tian K, Sun D, Chen M, Yang Y, Wang F, Guo T, et al. Long noncoding RNA X-inactive specific transcript facilitates cellular functions in melanoma via miR-139-5p/ROCK1 pathway. Onco Targets Ther. 2020;13:1277–87.
pubmed: 32103995
pmcid: 7024886
doi: 10.2147/OTT.S225661
Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.
pubmed: 17060945
doi: 10.1038/nrc1997
Sadakierska-Chudy A. MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics. Biomolecules. 2020;10:1285.
pmcid: 7565521
doi: 10.3390/biom10091285
Qu J, Li M, Zhong W, Hu C. Competing endogenous RNA in cancer: a new pattern of gene expression regulation. Int J Clin Exp Med. 2015;8:17110–6.
pubmed: 26770304
pmcid: 4694204
Zhang XZ, Liu H, Chen SR. Mechanisms of long non-coding RNAs in cancers and their dynamic regulations. Cancers. 2020;12:1245.
pmcid: 7281179
doi: 10.3390/cancers12051245
Ye Y, Shen A, Liu A. Long non-coding RNA H19 and cancer: A competing endogenous RNA. Bull Cancer. 2019;106:1152–9.
pubmed: 31753509
doi: 10.1016/j.bulcan.2019.08.011
Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Long noncoding RNA (lncRNA)-mediated competing endogenous rna networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20:5758.
pmcid: 6888455
doi: 10.3390/ijms20225758
Yan Y, Yan H, Teng Y, Wang Q, Yang P, Zhang L. et al. Long noncoding RNA 00507/miRNA-181c-5p/TTBK1/MAPT axis regulates tau hyperphosphorylation in Alzheimer’s disease. J Gene Med. 2020;22:e3268.
pubmed: 32891070
doi: 10.1002/jgm.3268
Xu X, Hao Y, Xiong S, He Z. Comprehensive analysis of long non-coding RNA-associated competing endogenous RNA network in Duchenne muscular dystrophy. Interdiscip Sci. 2020;12:447–60.
pubmed: 32876881
doi: 10.1007/s12539-020-00388-2
Meng Q, Wang X, Xue T, Zhao Q, Wang W, Zhao K. Long noncoding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis. Cancer Cell Int. 2020;20:414.
pubmed: 32874129
pmcid: 7457246
doi: 10.1186/s12935-020-01510-6
Xu HL, Tian FZ. Clinical significance of lncRNA MIR31HG in melanoma. Eur Rev Med Pharm Sci. 2020;24:4389–95.
Zhou X, Rao Y, Sun Q, Liu Y, Chen J, Bu W. Long noncoding RNA CPS1-IT1 suppresses melanoma cell metastasis through inhibiting Cyr61 via competitively binding to BRG1. J Cell Physiol. 2019;234:22017–27.
pubmed: 31111478
doi: 10.1002/jcp.28764
Wen L, Zheng Y, Wen X, Zhang Y, Zeng W. Increased expression of long noncoding RNA GAS6-AS2 promotes proliferation and inhibits apoptosis of melanoma cells via upregulating GAS6 expression. IUBMB Life. 2019;71:1503–14.
pubmed: 31162889
doi: 10.1002/iub.2071
An LF, Huang JW, Han X, Wang J. Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis. Anticancer Drugs. 2020;31:473–82.
pubmed: 32265386
doi: 10.1097/CAD.0000000000000888
Zou JX, Ge TW. Long non-coding RNA NEAT1 promotes tumor development and metastasis through targeting miR-224-5p in malignant melanoma. Eur Rev Med Pharm Sci. 2020;24:1302–8.
Wu L, Zhu L, Li Y, Zheng Z, Lin X, Yang C. LncRNA MEG3 promotes melanoma growth, metastasis and formation through modulating miR-21/E-cadherin axis. Cancer Cell Int. 2020;20:12.
pubmed: 31938020
pmcid: 6954595
doi: 10.1186/s12935-019-1087-4
Bi LL, Hua XQ, Li WH, Wang L, Li Y, Jia XF. SNHG16 promotes cell proliferation and migration through sponging miR-132 in melanoma. J Biol Regul Homeost Agents. 2020;34:1307–16.
pubmed: 32864914
Wang Y, Li D, Lu J, Chen L, Zhang S, Qi W, et al. Long noncoding RNA TTN-AS1 facilitates tumorigenesis and metastasis by maintaining TTN expression in skin cutaneous melanoma. Cell Death Dis. 2020;11:664.
pubmed: 32820147
pmcid: 7441063
doi: 10.1038/s41419-020-02895-y
Wang P, Hu L, Fu G, Lu J, Zheng Y, Li Y, et al. LncRNA MALAT1 promotes the proliferation, migration, and invasion of melanoma cells by downregulating miR-23a. Cancer Manag Res. 2020;12:6553–62.
pubmed: 32801893
pmcid: 7397564
doi: 10.2147/CMAR.S249348
Xu Y, Wang H, Li F, Heindl LM, He X, Yu J, et al. Long non-coding RNA LINC-PINT suppresses cell proliferation and migration of melanoma via recruiting EZH2. Front Cell Dev Biol. 2019;7:350.
pubmed: 31921860
pmcid: 6934058
doi: 10.3389/fcell.2019.00350
Yang Y, Xu W, Zheng Z, Cao Z. LINC00459 sponging miR-218 to elevate DKK3 inhibits proliferation and invasion in melanoma. Sci Rep. 2019;9:19139.
pubmed: 31844121
pmcid: 6914790
doi: 10.1038/s41598-019-55701-x
Li W, Chen Y, Nie XQ. Regulatory mechanisms of lncRNAs and their target gene signaling pathways in laryngeal squamous cell Carcinoma. Front Pharmacol. 2020;11:1140.
pubmed: 32848755
pmcid: 7397781
doi: 10.3389/fphar.2020.01140
Samimi H, Sajjadi-Jazi SM, Seifirad S, Atlasi R, Mahmoodzadeh H, Faghihi MA. et al. Molecular mechanisms of long non-coding RNAs in anaplastic thyroid cancer: a systematic review. Cancer Cell Int. 2020;20:352.
pubmed: 32760219
pmcid: 7392660
doi: 10.1186/s12935-020-01439-w
Qi XL, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710–8.
pubmed: 26358722
doi: 10.1136/jmedgenet-2015-103334
Peng SF, Yin XY, Zhang YZ, Mi WN, Li T, Yu Y, et al. Competing endogenous RNA network analysis reveals potential long non-coding RNAs as predictive biomarkers of gastric cancer. Oncol Lett 2020;19:2185–96.
pubmed: 32194716
pmcid: 7039062
Fang W, Fan YB, Fa ZZ, Xu JH, Yu HY, Li P, et al. microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma. Oncotarget 2017;8:13253–63.
pubmed: 28129648
pmcid: 5355093
doi: 10.18632/oncotarget.14710
Zhang HL, Feng C, Zhang MZ, Zeng A, Si LB, Yu NZ, et al. miR-625-5p/PKM2 negatively regulates melanoma glycolysis state. J Cell Biochem. 2019;120:2964–72.
pubmed: 30500994
doi: 10.1002/jcb.26917